FDA review finds no link between Singulair, suicide risk

01/13/2009 | Bloomberg

An updated FDA review found that Merck & Co.'s Singulair is not tied to a higher risk of suicide, but the agency said it is still looking into other psychiatric adverse reactions associated with the asthma drug. Merck said it "stands by the proven efficacy and safety of Singulair" and that data support the medicine's continued use.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care